Patient view: Getting lung cancer patient voices heard in health technology appraisals
This article was originally published in Scrip
Executive Summary
Lung cancer patients should have a louder voice in NICE health technology appraisals, say patient advocates as another new drug –Pfizer's Xalkori (crizotinib) – looks set to be rejected by the HTA.